Journal Home
Search for

Articles in Press

Return to articles in press list

Methadone as HIV prevention: High Volume Methadone Sites to decrease HIV incidence rates in resource limited settings

R. Douglas BruceCorresponding Author Informationemail address

Received 30 September 2009; received in revised form 12 October 2009; accepted 14 October 2009. published online 20 November 2009.
Corrected Proof

Abstract 

The link between injection drug use and HIV has been extensively described. Despite worldwide prevention efforts, injection drug use continues to be a risk factor for HIV transmission and both HIV and injection drug use continues to spread across the globe. Although methadone has demonstrated multiple health benefits including the reduction in injection drug use and HIV acquisition, the utilisation of methadone in many areas of the world remains one of secondary, rather than primary, HIV prevention. As a result, many who finally begin methadone enter treatment having accumulated medical and mental health problems as a result of delayed treatment. Rapid access to treatment and a more aggressive policy that realizes that methadone can help reduce opioid drug use is necessary if methadone is effectively going to act as primary HIV prevention. To delay access to methadone only increases the probability that the individual will acquire an infectious disease that is more costly to the individual in terms of morbidity and mortality and more costly to society as a whole.

Yale University, School of Medicine, AIDS Programme, 135 College Street, Suite 323, New Haven, CT 06510, United States

Corresponding Author InformationTel.: +1 203 688 2685; fax: +1 203 737 4051.

PII: S0955-3959(09)00130-3

doi:10.1016/j.drugpo.2009.10.004